Hiroshi Miyamoto MD, PhD, completed his medical school and urology residency training, followed by clinical urology practice and translational research in genitourinary cancers at Yokohama City University School of Medicine and affiliated hospitals in Japan. In 1996, he moved to the United States to conduct postdoctoral research at University of Wisconsin-Madison and University of Rochester. He then completed residency training in anatomic pathology at University of Rochester Medical Center and

more »

... clinical fellowship in urologic pathology at The Johns Hopkins Hospital. Since 2019, he has been the faculty as a surgical pathologist as well as an independent investigator at Sex steroids, including androgens, estrogens, and progestogens, are known to have widespread physiological actions beyond the reproductive system via binding to the sex hormone receptors, members of the nuclear receptor superfamily that function as ligand-inducible transcription factors. Meanwhile, emerging evidence has indicated that sex hormone receptor-mediated signals are involved in the development and progression of some malignancies, such as prostate and breast carcinomas, as well as others that have not traditionally been considered as endocrine-related neoplasms. This Special Issue "Sex Hormone Receptor Signals in Human Malignancies" aims to cover a variety of aspects of the potential role of sex hormone receptor-mediated signals in prostate cancer, breast cancer, and other neoplastic conditions. The current observations described may provide unique insights into novel or known functions of sex hormone receptors and related molecules. Hiroshi Miyamoto